-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the team of Professor Xu Xuewen of the Department of Plastic Surgery/Burns and the team of Professor Li Tao of the Laboratory of Mitochondrial and Metabolic Medicine of the Anesthesia Surgery Center jointly published a joint publication entitled "Signaling pathways in obesity: mechanisms and" in the well-known journals in the field of "Biochemistry and Molecular Biology" signal transduction and Targeted Therapy (IF: 38.
Wenxue Assistant Researcher of Plastic Surgery/Burn Science, Assistant Researcher Zhang Bohan, Deputy Chief Physician Xiao Haitao and Dr.
Obesity is a chronic systemic disease with a complex pathogenesis and a global public health challenge
In this review, Professor Xu Xuewen's team and Professor Li Tao's team comprehensively summarized the latest research progress of obesity, and comprehensively elaborated the regulatory mechanism of obesity-related signaling pathways/signaling molecules from the aspects of appetite regulation, glucose homeostasis, lipogenesis, body thermogenesis and chronic inflammation (Figure 1
Figure 1: Signaling pathways involved in the pathogenesis of obesity
Subsequently, the team outlined the history of the development of FDA-approved anti-obesity drugs in the United States (Figure 2), as well as the current research status of anti-obesity drugs for the signaling pathways/signaling molecules described
Figure 2: History of the development of anti-obesity drugs
